Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

High Density Lipoprotein Cholesterol and Statin Trials

Author(s): Anna Kakafika, Vasilios G. Athyros, Konstantinos Tziomalos, Asterios Karagiannis and Dimitri P. Mikhailidis

Volume 15 , Issue 22 , 2008

Page: [2265 - 2270] Pages: 6

DOI: 10.2174/092986708785747481

Price: $65

Abstract

Epidemiological studies show that high density lipoprotein cholesterol (HDL-C) levels are inversely related to the risk of vascular events. Statins are the most widely prescribed drugs for the treatment of dyslipidaemias and their use for the prevention of vascular events is evidence based. Statins raise HDL-C but this effect seems to vary considerably between studies. We searched the literature to assess the relationship between statin-induced increases in HDL-C levels and surrogate and/or clinical endpoints. Based on the existing evidence, it is difficult to determine how much reduction, if any, in vascular risk is attributable to a statin-induced increment in HDL-C levels. Whether a statin that beyond its LDL-C lowering effect also raises HDL-C has additional benefits in the prevention of vascular events remains to be established.

Keywords: High density lipoprotein cholesterol, vascular risk, statins, intravascular ultrasound, carotid intima media thickness


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy